Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560661 | 0.91 | HPGD (0.53) | HPGDNPC1ALDH1A1KMT2ABRD4 | |
| SCHEMBL3560317 | 0.89 | HPGD (0.69) | HPGDALDH1A1HSD17B10TSHRKMT2A | |
| SCHEMBL3555543 | 0.88 | HPGD (0.50) | HPGDALDH1A1HTR6 | |
| SCHEMBL3557393 | 0.87 | HPGD (0.59) | HPGDHSD17B10KMT2AHDAC1ALOX15 | |
| SCHEMBL6797222 | 0.85 | HPGD (0.58) | HPGDNPC1ALDH1A1HSD17B10KMT2A | |
| SCHEMBL3555628 | 0.84 | HTR6 (0.65) | KMT2AHDAC1HTR6SLC16A3 | |
| SCHEMBL3559365 | 0.84 | ALDH1A1 (0.52) | HPGDALDH1A1KMT2AHTR6 | |
| SCHEMBL1650346 | 0.83 | HPGD (0.77) | HPGDALDH1A1HSD17B10TSHRKMT2A | |
| SCHEMBL3555871 | 0.83 | POLB (0.60) | KMT2AHTR6SLC16A3 | |
| SCHEMBL3552764 | 0.83 | RARB (0.47) | HPGDALDH1A1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | HPGD 389/4885NPC1 2684/4885ALDH1A1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.